Terms: = Ovarian cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
14 results:
1. cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.
Feng S; Ding B; Dai Z; Yin H; Ding Y; Liu S; Zhang K; Lin H; Xiao Z; Shen Y
J Transl Med; 2024 Mar; 22(1):280. PubMed ID: 38491511
[TBL] [Abstract] [Full Text] [Related]
2. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
3. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
[TBL] [Abstract] [Full Text] [Related]
4. Generation of high-affinity, internalizing anti-fgfr2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.
Borek A; Sokolowska-Wedzina A; Chodaczek G; Otlewski J
PLoS One; 2018; 13(2):e0192194. PubMed ID: 29420662
[TBL] [Abstract] [Full Text] [Related]
5. Alofanib, an allosteric fgfr2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the treatment of fgfr2-Positive Solid Tumors.
Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B
Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601
[TBL] [Abstract] [Full Text] [Related]
7. Targeting fgfr2 with alofanib (RPT835) shows potent activity in tumour models.
Tsimafeyeu I; Ludes-Meyers J; Stepanova E; Daeyaert F; Khochenkov D; Joose JB; Solomko E; Van Akene K; Peretolchina N; Yin W; Ryabaya O; Byakhov M; Tjulandin S
Eur J Cancer; 2016 Jul; 61():20-8. PubMed ID: 27136102
[TBL] [Abstract] [Full Text] [Related]
8. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.
Martignetti JA; Camacho-Vanegas O; Priedigkeit N; Camacho C; Pereira E; Lin L; Garnar-Wortzel L; Miller D; Losic B; Shah H; Liao J; Ma J; Lahiri P; Chee M; Schadt E; Dottino P
Neoplasia; 2014 Jan; 16(1):97-103. PubMed ID: 24563622
[TBL] [Abstract] [Full Text] [Related]
9. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.
Gadducci A; Sergiampietri C; Guiggi I
Gynecol Endocrinol; 2013 Sep; 29(9):811-6. PubMed ID: 23767831
[TBL] [Abstract] [Full Text] [Related]
10. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.
Smith G; Ng MT; Shepherd L; Herrington CS; Gourley C; Ferguson MJ; Wolf CR
Br J Cancer; 2012 Oct; 107(8):1327-36. PubMed ID: 22990650
[TBL] [Abstract] [Full Text] [Related]
11. [Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies].
Stoppa-Lyonnet D; Buecher B; Houdayer C; de Pauw A; Gauthier-Villars M; de la Rochefordière A; This P; Asselain B; Andrieu N
Bull Acad Natl Med; 2009 Dec; 193(9):2063-83; discussion 2084-5. PubMed ID: 20690207
[TBL] [Abstract] [Full Text] [Related]
12. Inhibition of fgfr2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.
Cole C; Lau S; Backen A; Clamp A; Rushton G; Dive C; Hodgkinson C; McVey R; Kitchener H; Jayson GC
Cancer Biol Ther; 2010 Sep; 10(5):495-504. PubMed ID: 20595807
[TBL] [Abstract] [Full Text] [Related]
13. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.
Garcia-Closas M; Hall P; Nevanlinna H; Pooley K; Morrison J; Richesson DA; Bojesen SE; Nordestgaard BG; Axelsson CK; Arias JI; Milne RL; Ribas G; González-Neira A; Benítez J; Zamora P; Brauch H; Justenhoven C; Hamann U; Ko YD; Bruening T; Haas S; Dörk T; Schürmann P; Hillemanns P; Bogdanova N; Bremer M; Karstens JH; Fagerholm R; Aaltonen K; Aittomäki K; von Smitten K; Blomqvist C; Mannermaa A; Uusitupa M; Eskelinen M; Tengström M; Kosma VM; Kataja V; Chenevix-Trench G; Spurdle AB; Beesley J; Chen X; ; ; Devilee P; van Asperen CJ; Jacobi CE; Tollenaar RA; Huijts PE; Klijn JG; Chang-Claude J; Kropp S; Slanger T; Flesch-Janys D; Mutschelknauss E; Salazar R; Wang-Gohrke S; Couch F; Goode EL; Olson JE; Vachon C; Fredericksen ZS; Giles GG; Baglietto L; Severi G; Hopper JL; English DR; Southey MC; Haiman CA; Henderson BE; Kolonel LN; Le Marchand L; Stram DO; Hunter DJ; Hankinson SE; Cox DG; Tamimi R; Kraft P; Sherman ME; Chanock SJ; Lissowska J; Brinton LA; Peplonska B; Klijn JG; Hooning MJ; Meijers-Heijboer H; Collee JM; van den Ouweland A; Uitterlinden AG; Liu J; Lin LY; Yuqing L; Humphreys K; Czene K; Cox A; Balasubramanian SP; Cross SS; Reed MW; Blows F; Driver K; Dunning A; Tyrer J; Ponder BA; Sangrajrang S; Brennan P; McKay J; Odefrey F; Gabrieau V; Sigurdson A; Doody M; Struewing JP; Alexander B; Easton DF; Pharoah PD
PLoS Genet; 2008 Apr; 4(4):e1000054. PubMed ID: 18437204
[TBL] [Abstract] [Full Text] [Related]
14. Features of Antley-Bixler syndrome in an infant born to a mother with pregnancy luteoma.
Roth C; Hinney B; Peter M; Steinberger D; Lakomek M
Eur J Pediatr; 2000 Mar; 159(3):189-92. PubMed ID: 10664233
[TBL] [Abstract] [Full Text] [Related]
